This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding Phase II clinical trial aimed to determine the optimal dose of LV232 capsules for treating MDD, evaluate preliminary efficacy and safety, and provide a basis for Phase III trial design and dosing regimen determination.
Protocol Amendment History
3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-02-10; most recent amendment 2026-05-18.
Status change: Not Yet Recruiting → Recruiting2025-04-18